Vernalis Considers US Deals As Prescription Cough/Cold Strategy Delivers
This article was originally published in The Pink Sheet Daily
Executive Summary
Vernalis launches its first long-acting liquid cough and cold product, Tuzistra XR, in the US as part of a revised business focus on generating sustainable revenues from low development risk, late-stage products.
You may also be interested in...
Vernalis Raises $100 million To Support Push Into U.S. Rx Cough/Cold Market
Vernalis reveals new strategy to market long-acting prescription cough/cold preparations in the US, supported by Tris Pharma's technology and a $104 million fundraising
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.